These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32075800)

  • 1. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
    Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
    Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.
    Miller AM; Bahmanof M; Zehn D; Cohen EEW; Schoenberger SP
    Cancer Immunol Res; 2019 Jan; 7(1):40-49. PubMed ID: 30482746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
    Hebeisen M; Baitsch L; Presotto D; Baumgaertner P; Romero P; Michielin O; Speiser DE; Rufer N
    J Clin Invest; 2013 Mar; 123(3):1044-56. PubMed ID: 23391724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments.
    Xie YJ; Dougan M; Ingram JR; Pishesha N; Fang T; Momin N; Ploegh HL
    Cancer Immunol Res; 2020 Apr; 8(4):518-529. PubMed ID: 32019780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
    Stromnes IM; Fowler C; Casamina CC; Georgopolos CM; McAfee MS; Schmitt TM; Tan X; Kim TD; Choi I; Blattman JN; Greenberg PD
    J Immunol; 2012 Aug; 189(4):1812-25. PubMed ID: 22798667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
    Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
    J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading.
    Xin G; Khatun A; Topchyan P; Zander R; Volberding PJ; Chen Y; Shen J; Fu C; Jiang A; See WA; Cui W
    Cancer Immunol Res; 2020 Jan; 8(1):7-18. PubMed ID: 31719059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.
    Watson HA; Dolton G; Ohme J; Ladell K; Vigar M; Wehenkel S; Hindley J; Mohammed RN; Miners K; Luckwell RA; Price DA; Matthews RJ; Ager A
    Immunol Cell Biol; 2016 Sep; 94(8):802-8. PubMed ID: 27430370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D defines tumor-reacting effector CD8
    Mojic M; Shitaoka K; Ohshima C; Ucche S; Lyu F; Hamana H; Tahara H; Kishi H; Hayakawa Y
    Cancer Sci; 2021 Sep; 112(9):3484-3490. PubMed ID: 34187084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
    Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
    Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.